Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
KHAN Technology Transfer Fund I is an early-stage venture fund based in Europe, focusing on life sciences. Founded to create value through partnerships with academic innovators, it targets first-in-class therapies for high unmet medical needs. The fund supports over 10 startups and has funded more than 50 scientific assets.
This fund invests in early-stage life sciences projects, particularly first-in-class therapeutics. It emphasizes technology transfer in drug discovery and collaborates with academic institutions like the Max Planck Society. KHAN provides flexible funding and support, allowing projects to develop without needing fully validated assets or complete teams initially.
Submit your pitch through their form at khan-i.de.
Yes, KHAN Technology Transfer Fund I often leads investment rounds in the early stages of life sciences projects.
The fund is open to follow-on investments, particularly if the projects show promising development and potential for commercialization.
The specific size of the current fund is not disclosed, but it focuses on early-stage investments in biotech and healthcare.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.